Oryzon Genomics S.A.
ORYZF · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | – | $31,113 | – | $5,619 |
| Short-Term Investments | – | $0 | – | $0 |
| Receivables | – | $1,767 | – | $1,384 |
| Inventory | – | $6 | – | $3 |
| Other Curr. Assets | – | $1,250 | – | $1,742 |
| Total Curr. Assets | – | $34,136 | – | $8,748 |
| Property Plant & Equip (Net) | – | $311 | – | $356 |
| Goodwill | – | $0 | – | $0 |
| Intangibles | – | $101,356 | – | $97,096 |
| Long-Term Investments | – | $0 | – | $0 |
| Tax Assets | – | $2,422 | – | $2,390 |
| Other NC Assets | – | $126 | – | $127 |
| Total NC Assets | – | $104,215 | – | $99,969 |
| Other Assets | – | $0 | – | $0 |
| Total Assets | – | $138,351 | – | $108,716 |
| Liabilities | – | – | – | – |
| Payables | – | $2,104 | – | $2,126 |
| Short-Term Debt | – | $8,661 | – | $7,924 |
| Tax Payable | – | $274 | – | $223 |
| Deferred Revenue | – | $0 | – | $0 |
| Other Curr. Liab. | – | $1,947 | – | $1,443 |
| Total Curr. Liab. | – | $13,010 | – | $11,739 |
| LT Debt | – | $5,024 | – | $3,222 |
| Deferred Rev, NC | – | $0 | – | $0 |
| Deferred Tax Liab, NC | – | $2,422 | – | $2,390 |
| Other NC Liab. | – | $3,650 | – | $4,289 |
| Total NC Liab. | – | $11,118 | – | $9,935 |
| Other Liabilities | – | $0 | – | $0 |
| Cap. Leases | – | $46 | – | $57 |
| Total Liabilities | – | $24,128 | – | $21,674 |
| Equity | – | – | – | – |
| Pref Stock | – | $0 | – | $0 |
| Common Stock | – | $3,927 | – | $3,289 |
| Retained Earnings | – | -$20,931 | – | -$19,336 |
| AOCI | – | $0 | – | $0 |
| Other Equity | – | $3,180 | – | $4,405 |
| Total Equity | – | $114,223 | – | $87,042 |
| Supplemental Information | – | – | – | – |
| Minority Interest | – | $0 | – | $0 |
| Total Liab. & Tot. Equity | – | $138,351 | – | $108,716 |
| Net Debt | $0 | -$17,429 | $0 | $5,528 |